Symbol | Exchange | Currency |
|---|
(Reuters) - Britain's Clinigen Group Plc has agreed to a sweetened takeover offer by UK-based private equity firm Triton, valuing the pharmaceutical services firm at about 1.3...
(Reuters) - Activist investor Elliott Management has further raised its stake in pharmaceutical services group and takeover target Clinigen Group Plc, a filing showed on Thursday....
By Pushkala Aripaka (Reuters) - Clinigen on Wednesday agreed to be bought by UK-based Triton Investment Management in a deal that values the pharmaceutical services group at about...
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom. As of April 4, 2022, Clinigen Group plc was taken private.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 85.32 | 86.98 | 84.18 | +2.16 | +2.60% | 26.30M | London | |||
| 102.40 | 103.40 | 99.50 | +1.00 | +0.99% | 141.75K | London | |||
| 255.30 | 259.60 | 253.50 | -3.00 | -1.16% | 35.92M | London | |||
| 1,458.00 | 1,474.00 | 1,444.50 | +6.00 | +0.41% | 985.23K | London | |||
| 2,351.00 | 2,369.00 | 2,301.00 | +49.0 | +2.13% | 1.34M | London | |||
| 318.00 | 318.20 | 289.80 | +37.20 | +13.25% | 2.86M | London | |||
| 6,690.00 | 6,846.00 | 6,628.00 | -62.0 | -0.92% | 241.31K | London | |||
| 2,193.00 | 2,221.00 | 2,177.00 | +22.0 | +1.01% | 543.68K | London | |||
| 434.80 | 439.80 | 428.50 | +6.10 | +1.42% | 8.29M | London | |||
| 847.00 | 867.00 | 831.50 | +4.00 | +0.47% | 750.84K | London | |||
| 6,212.00 | 6,242.00 | 6,158.00 | -18.0 | -0.29% | 709.11K | London | |||
| 905.20 | 911.80 | 876.00 | +29.60 | +3.38% | 4.98M | London | |||
| 6.67 | 7.85 | 5.51 | -0.63 | -8.63% | 9.33M | London | |||
| 260.20 | 260.80 | 255.60 | +4.20 | +1.64% | 1.08M | London | |||
| 3,635.00 | 3,650.00 | 3,560.00 | +50.0 | +1.40% | 13.52K | London |